|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thatcher N, Chang A, Parikh P, Pereira
Rodrigues J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH,
Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive
care in previously treated patients with refractory advanced
non-small-cell lung cancer: Results from a randomised,
placebo-controlled, multicentre study (Iressa Survival Evaluation
in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suda K, Murakami I, Katayama T, Tomizawa
K, Osada H, Sekido Y, Maehara Y, Yatabe Y and Mitsudomi T:
Reciprocal and complementary role of MET amplification and EGFR
T790M mutation in acquired resistance to kinase inhibitors in lung
cancer. Clin Cancer Res. 16:5489–5498. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van der Pol E, Böing AN, Harrison P, Sturk
A and Nieuwland R: Classification, functions, and clinical
relevance of extracellular vesicles. Pharmacol Rev. 64:676–705.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Katakowski M, Buller B, Zheng X, Lu Y,
Rogers T, Osobamiro O, Shu W, Jiang F and Chopp M: Exosomes from
marrow stromal cells expressing miR-146b inhibit glioma growth.
Cancer Lett. 335:201–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vlassov AV, Magdaleno S, Setterquist R and
Conrad R: Exosomes: Current knowledge of their composition,
biological functions, and diagnostic and therapeutic potentials.
Biochim Biophys Acta. 1820:940–948. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lv MM, Zhu XY, Chen WX, Zhong SL, Hu Q, Ma
TF, Zhang J, Chen L, Tang JH and Zhao JH: Exosomes mediate drug
resistance transfer in MCF-7 breast cancer cells and a probable
mechanism is delivery of P-glycoprotein. Tumour Biol.
35:10773–10779. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiao X, Yu S, Li S, Wu J, Ma R, Cao H, Zhu
Y and Feng J: Exosomes: Decreased sensitivity of lung cancer A549
cells to cisplatin. PloS One. 9:e895342014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu SW, Cao HX, Wu JZ, Ma R, Jing CW, Wang
Z and Feng JF: Difference of miRNA-7 expression in the non-small
cell lung cancer with different sensitivity to gefitinib and their
clinical significance. Chin J Surg Onco. 7:74–77. 2015.
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li S, Liang Z, Xu L and Zou F:
MicroRNA-21: A ubiquitously expressed pro-survival factor in cancer
and other diseases. Mol Cell Biochem. 360:147–158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang ZX, Lu BB, Wang H, Cheng ZX and Yin
YM: MicroRNA-21 modulates chemosensitivity of breast cancer cells
to doxorubicin by targeting PTEN. Arch Med Res. 42:281–290. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ziyan W and Yang L: MicroRNA-21 regulates
the sensitivity to cisplatin in a human osteosarcoma cell line. Ir
J Med Sci. 185:85–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li B, Ren S, Li X, Wang Y, Garfield D,
Zhou S, Chen X, Su C, Chen M, Kuang P, et al: MiR-21 overexpression
is associated with acquired resistance of EGFR-TKI in non-small
cell lung cancer. Lung Cancer. 83:146–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang JM, He QY, Guo RX and Chang XJ:
Phosphorylated Akt overexpression and loss of PTEN expression in
non-small cell lung cancer confers poor prognosis. Lung Cancer.
51:181–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Masyuk AI, Masyuk TV and Larusso NF:
Exosomes in the pathogenesis, diagnostics and therapeutics of liver
diseases. J Hepatol. 59:621–625. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vella LJ, Sharples RA, Nisbet RM, Cappai R
and Hill AF: The role of exosomes in the processing of proteins
associated with neurodegenerative diseases. Eur Biophys J.
37:323–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu DD, Wu Y, Zhang XH, Lv MM, Chen WX,
Chen X, Yang SJ, Shen H, Zhong SL, Tang JH and Zhao JH: Exosomes
from adriamycin-resistant breast cancer cells transmit drug
resistance partly by delivering miR-222. Tumour Biol. 37:3227–3235.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yeung Au CL, Co NN, Tsuruga T, Yeung TL,
Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, et al: Exosomal
transfer of stroma-derived miR21 confers paclitaxel resistance in
ovarian cancer cells through targeting APAF1. Nat Commun.
7:111502016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Corcoran C, Rani S, O'Brien K, O'Neill A,
Prencipe M, Sheikh R, Webb G, McDermott R, Watson W, Crown J and
O'Driscoll L: Docetaxel-resistance in prostate cancer: Evaluating
associated phenotypic changes and potential for resistance transfer
via exosomes. PloS One. 7:e509992012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li XQ, Liu JT, Fan LL, Liu Y, Cheng L,
Wang F, Yu HQ, Gao J, Wei W, Wang H and Sun GP: Exosomes derived
from gefitinib-treated EGFR-mutant lung cancer cells alter
cisplatin sensitivity via up-regulating autophagy. Oncotarget.
7:24585–24595. 2016.PubMed/NCBI
|
|
26
|
Valadi H, Ekström K, Bossios A, Sjöstrand
M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and
microRNAs is a novel mechanism of genetic exchange between cells.
Nat Cell Biol. 9:654–659. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Capodanno A, Boldrini L, Proietti A, Alì
G, Pelliccioni S, Niccoli C, D'Incecco A, Cappuzzo F, Chella A,
Lucchi M, et al: Let-7g and miR-21 expression in non-small cell
lung cancer: Correlation with clinicopathological and molecular
features. Int J Oncol. 43:765–774. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu ZL, Wang H, Liu J and Wang ZX:
MicroRNA-21 (miR-21) expression promotes growth, metastasis, and
chemo- or radioresistance in non-small cell lung cancer cells by
targeting PTEN. Mol Cell Biochem. 372:35–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wei X, Wang W, Wang L, Zhang Y, Zhang X,
Chen M, Wang F, Yu J, Ma Y and Sun G: MicroRNA-21 induces
5-fluorouracil resistance in human pancreatic cancer cells by
regulating PTEN and PDCD4. Cancer Med. 5:693–702. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Echevarría-Vargas IM, Valiyeva F and
Vívas-Mejia PE: Upregulation of miR-21 in cisplatin resistant
ovarian cancer via JNK-1/c-Jun pathway. PloS One. 9:e970942014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen Y, Tsai YH, Fang Y and Tseng SH:
Micro-RNA-21 regulates the sensitivity to cisplatin in human
neuroblastoma cells. J Pediatr Surg. 47:1797–1805. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang S, Su X, Bai H, Zhao J, Duan J, An T,
Zhuo M, Wang Z, Wu M, Li Z, et al: Identification of plasma
microRNA profiles for primary resistance to EGFR-TKIs in advanced
non-small cell lung cancer (NSCLC) patients with EGFR activating
mutation. J Hematol Oncol. 8:1272015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen H, Zhu F, Liu J, Xu T, Pei D, Wang R,
Qian Y, Li Q, Wang L, Shi Z, et al: Alteration in Mir-21/PTEN
expression modulates gefitinib resistance in non-small cell lung
cancer. PloS One. 9:e1033052014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li H, Schmid-Bindert G, Wang D, Zhao Y,
Yang X, Su B and Zhou C: Blocking the PI3K/AKT and MEK/ERK
signaling pathways can overcome gefitinib-resistance in non-small
cell lung cancer cell lines. Adv Med Sci. 56:275–284. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yan LX, Liu YH, Xiang JW, Wu QN, Xu LB,
Luo XL, Zhu XL, Liu C, Xu FP, Luo DL, et al: PIK3R1 targeting by
miR-21 suppresses tumor cell migration and invasion by reducing
PI3K/AKT signaling and reversing EMT, and predicts clinical outcome
of breast cancer. Int J Oncol. 48:471–484. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song L, Liu S, Zhang L, Yao H, Gao F, Xu D
and Li Q: MiR-21 modulates radiosensitivity of cervical cancer
through inhibiting autophagy via the PTEN/Akt/HIF-1α feedback loop
and the Akt-mTOR signaling pathway. Tumour Biol. 37:12161–12168.
2016. View Article : Google Scholar : PubMed/NCBI
|
